贝瑞基因(000710) - 000710贝瑞基因投资者关系管理信息20250224

Group 1: Company Overview and Mission - Beirui Gene has focused on creating a new future in gene technology for 15 years, aiming to enhance human well-being through innovation [2] - The company operates in over 30 provinces and regions in China, as well as in Southeast Asia, the Middle East, and Australia, collaborating with over 2,000 hospitals [2] - Beirui has provided gene testing services to over 5 million individuals, alleviating economic burdens exceeding 100 billion yuan for society and families [2] Group 2: Genetic Testing and AI Integration - In the field of genetic disease testing, Beirui is developing a comprehensive diagnostic platform that offers various testing combinations for prenatal, pediatric, and adult genetic disease detection [2] - The company has built a vast medical knowledge graph by accumulating extensive experimental, research, and clinical data, which supports AI applications in healthcare [2][3] - The core value of AI in healthcare is to reconstruct the medical ecosystem, with plans to collaborate with top medical institutions for multi-omics data training [3] Group 3: Health Management Model and Data Utilization - Beirui's health management model is designed to provide rapid and accurate information on rare diseases, significantly improving decision-making efficiency [5] - The data lake contains over 10 million clinical diagnosis records and hundreds of billions of tokens, forming a knowledge graph with nearly 1 billion nodes and edges [5] - The company ensures data quality and security through strict compliance with national regulations, transforming individual data into group data for better analysis [6][7] Group 4: Collaboration and Future Projects - In January 2025, Beirui successfully delivered and tested the first batch of the Vega desktop long-read sequencing platform in collaboration with PacBio [7] - The company is accelerating the development and clinical registration of the Chinese version of the Vega CNDx model, aiming for overseas market approval [7]